论文部分内容阅读
目的:探讨沙美特罗替卡松治疗稳定型慢阻肺的临床疗效及对肺功能的影响,旨在为临床治疗提供有效依据.方法:选取2014-12/2015-12新疆维吾尔自治区克拉玛依市独山子人民医院呼吸内科收治的96例稳定型慢阻肺患者,随机分为实验组(n=48)和对照组(n=48).其中对照组采用常规方法进行治疗,实验组在对照组的基础上加用沙美特罗替卡松进行治疗.回顾性分析两组患者治疗后临床症状的改善情况,同时通过对患者相关肺功能指标的比较,探讨沙美特罗替卡松治疗稳定型慢阻肺的疗效及对肺功能的影响.结果:治疗前,两组患者相关肺功能指标、呼吸困难程度评分比较,差异无统计学意义(P>0.05).治疗6个月后,两组患者的FEV1、FEV1/FVC均有一定程度的提高,呼吸困难程度评分均较治疗前降低,但实验组患者肺功能指标提高水平较对照组明显,实验组患者呼吸困难程度评分降低水平较对照组明显,差异均具有统计学意义(P<0.05).结论:沙美特罗替卡松治疗稳定型慢阻肺有显著疗效,对COPD患者的肺功能有所改善,值得临床推广.
Objective: To investigate the clinical efficacy of salmeterol and fluticasone in the treatment of stable COPD and its influence on pulmonary function, and to provide an effective basis for clinical treatment.Methods: Select the city of Karamay in Xinjiang Uygur Autonomous Region from December 2014 to December 2015 96 patients with stable chronic obstructive pulmonary disease who were admitted to Department of Respiratory Medicine, Shanzi People’s Hospital were randomly divided into experimental group (n = 48) and control group (n = 48), the control group was treated by conventional method, Based on the use of salmeterol and fluticasone for treatment.Review of two groups of patients after treatment to improve the clinical symptoms, and through the comparison of the patient’s lung function indicators to explore the salmeterol / Lung efficacy and lung function.Results: Before treatment, the two groups of patients with lung function index, degree of dyspnea score comparison, the difference was not statistically significant (P> 0.05) .After 6 months of treatment, the two groups of patients FEV1, FEV1 / FVC were improved to a certain extent, the score of dyspnea was lower than before treatment, but the level of lung function in experimental group was significantly higher than that in control group, and the level of dyspnea score in experimental group was lower Control group significantly, the differences were statistically significant (P <0.05) Conclusion: salmeterol fluticasone patients with stable chronic obstructive pulmonary disease have a significant effect on lung function in patients with COPD has improved, worthy of promotion.